CD7 CAR-T cells is named as a drug or biological intervention in 6 clinical trials in our China trial register, 5 of which are recruiting. Lead sponsors include Zhejiang University (3), Shenzhen University General Hospital (1) and Xuzhou Medical University (1). Registered phases: Phase EARLY_PHASE1, Phase 1/2, Not applicable and Observational. Conditions studied include T Lymphoblastic Leukemia/Lymphoma; Schimke Immuno-osseous Dysplasia; Aplastic Anaemia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06633328 | CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia (ClinicalTrials.gov ↗) Aplastic Anemia |
Phase EARLY_PHASE1 | Recruiting |
| NCT06769191 | Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD (ClinicalTrials.gov ↗) Schimke Immuno-osseous Dysplasia |
Phase EARLY_PHASE1 | Recruiting |
| NCT05827835 | CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases (ClinicalTrials.gov ↗) Hematologic Diseases, Neoplasms |
Phase 1/2 | Recruiting |
| NCT06925464 | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas (ClinicalTrials.gov ↗) T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL) |
Phase 1/2 | Recruiting |
| NCT05620680 | CD7 CAR-T Cells in T-cell Lymphoma/Leukemia (ClinicalTrials.gov ↗) T Lymphoblastic Leukemia/Lymphoma |
Not applicable | Recruiting |
| NCT07139600 | Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy (ClinicalTrials.gov ↗) Aplastic Anaemia, CAR-T, CD7 Positive |
Observational | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| T Lymphoblastic Leukemia/Lymphoma | 1 |
| Schimke Immuno-osseous Dysplasia | 1 |
| Aplastic Anaemia | 1 |
| CAR-T | 1 |
| CD7 Positive | 1 |
| T-Cell Non-Hodgkin Lymphoma | 1 |
| T-cell Lymphoma (PTCL and CTCL) | 1 |
| Hematologic Diseases | 1 |
| Neoplasms | 1 |
| Aplastic Anemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Zhejiang University | 3 |
| Shenzhen University General Hospital | 1 |
| Xuzhou Medical University | 1 |
| Beijing GoBroad Hospital | 1 |
| Register | CD7 CAR-T cells trials |
|---|---|
| Clinical trials in China | 6 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CD7 CAR-T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CD7 CAR-T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.